Yes, patients with hepatitis C-related cirrhosis and HCC should receive antiviral therapy with direct-acting antivirals (DAAs).
Patients with hepatocellular carcinoma and hepatitis C-related cirrhosis should be treated with DAAs, as this reduces mortality, prevents waitlist dropout in transplant candidates, and decreases HCC recurrence after curative treatment. 1
Treatment Timing Based on HCC Status
For HCC Eligible for Curative Treatment (Resection/Ablation)
Defer DAA therapy until after HCC treatment is completed if the patient has compensated (Child-Pugh A) cirrhosis and is undergoing liver resection or ablation 1. This approach optimizes SVR rates, which are higher in patients who receive curative HCC therapy first (88% with curative therapy vs. lower rates without).
For HCC Awaiting Liver Transplantation
The timing requires multidisciplinary discussion and depends on waiting time:
- In centers with long waiting times: Initiate HCV treatment before transplantation to facilitate locoregional therapies and reduce waitlist dropout due to tumor progression 1
- In centers with short waiting times: Treatment can be deferred to post-transplant period
- A retrospective study of 149 transplant candidates showed DAA-treated patients had lower risk of waitlist dropout from tumor progression or death 1
For Treated HCC Without Transplant Indication
Treat with DAAs after successful HCC treatment to reduce recurrence risk and improve survival 1. DAA-induced SVR substantially reduces:
- De novo HCC incidence
- All-cause mortality
- Liver-related mortality in mid- to long-term 1
Key Evidence Supporting Treatment
The 2020 EASL guidelines 1 provide the strongest evidence that:
SVR rates in HCC patients are acceptable: 88% overall SVR rate in meta-analysis of 5,522 HCC patients, though slightly lower than the 92% in non-HCC patients 1
Clinical benefits are substantial: Post-liver transplantation HCV treatment is cost-effective in HCC patients 1
Risk persists but is reduced: While HCC risk is not abolished by SVR, it is substantially reduced. Veterans Administration data shows increased HCC risk persists up to 10 years post-SVR in cirrhotic patients, justifying continued surveillance 1
Important Caveats
- All cirrhotic patients require ongoing HCC surveillance even after achieving SVR, as the cancer risk is reduced but not eliminated 1, 2
- Child-Pugh class matters: Treatment should be prioritized in compensated cirrhosis (Child-Pugh A). Decompensated patients can be treated but require careful selection 3, 4
- Avoid delays in HCC management: The timing of antiviral treatment should never interfere with optimal HCC management on the transplant waiting list 1
Treatment Regimen Selection
Use pangenotypic DAA regimens appropriate for cirrhosis 2. Specific regimens depend on:
- Degree of hepatic decompensation
- HCV genotype (if known)
- Drug-drug interactions with HCC treatments
- Renal function (sofosbuvir contraindicated if GFR <30 mL/min) 3